Indications
Treatment of rheumatoid arthritis.
Composition
- Active substance
- tofacitinib
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Xeljanz
- Active substance
- tofacitinib
- Therapeutic area
- Arthritis, Rheumatoid
- Marketing authorisation holder
- Pfizer Limited
- Status
- Refused
- Refused
- 25 Jul 2013
- EMA product number
- EMEA/H/C/002542
EMA designations
- Orphan medicine
- No
- Conditional approval
- No
- Biosimilar
- No
- Generic
- No
- Accelerated assessment
- No
- Additional monitoring
- No
- Patient safety information
- No